Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312771 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jun He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Medical Bioinformatics, Department of Bioinformatics, Institute of Precision Medicine, School of Medical Technology and Engi…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Leucovorin, Fluorouracil, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Medical University Research Foundation of Talented Scholars, Natural Science Foundation of Fujian Province, Youth Scientific Research Fund Program of School of Medical Technology and Engineering, Fujian Medical University.
Abstract (Originalsprache)
FOLFIRI (5-FU, leucovorin, irinotecan) is the first-line chemotherapy for metastatic colorectal cancer (mCRC), but response rates are under 50%. This study aimed to develop a predictive signature for FOLFIRI response in mCRC patients. Firstly, Spearman’s rank correlation and Wilcoxon rank-sum test were used to select chemotherapy response genes and gene pairs, respectively. Then, an optimization procedure was used to determine the final signature. A predictive signature consisting of three gene pairs (3-GPS) was identified. In the training set, 3-GPS achieved an accuracy of 0.94. In a validation set of 60 samples, predicted responders had significantly better progression-free survival than the predicted non-responders (HR = 0.47, p = 0.01). A comparable result was observed in an additional validation set of 27 samples (HR = 0.06, p = 0.02). The co-expressed genes of the signature were enriched in pathways associated with the immunotherapy response, and they interacted extensively with FOLFIRI-related genes. Notably, the expression of signature genes significantly correlated with various immune cell types, including plasma cells and memory-resting CD4+ T cells. In conclusion, the REO-based signature effectively identifies mCRC patients likely to benefit from FOLFIRI. Furthermore, these signature genes may play a crucial role in the chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Medical Bioinformatics, Department of Bioinformatics, Institute of Precision Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China.
- Key Laboratory Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China.
- School of Nursing, Fujian Medical University, Fuzhou 350122, China.
ORCID-Profile: Jun He, Xiaopei Shen
Förderung
- Fujian Medical University Research Foundation of Talented Scholars
- Natural Science Foundation of Fujian Province
- Youth Scientific Research Fund Program of School of Medical Technology and Engineering, Fujian Medical University
- Startup Fund for Scientific Research, Fujian Medical University
Zitieren
APA
He, J., Wang, M., Wu, D., Fu, H., & Shen, X. (2024). Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312771
Vancouver
He J, Wang M, Wu D, Fu H, Shen X. Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312771
BibTeX
@article{He2024,
author = {He, Jun and Wang, Mengyao and Wu, Dandan and Fu, Hao and Shen, Xiaopei},
title = {Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312771}
}
EUVIMED